BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11346705)

  • 1. Peripheral blood progenitor cell collection after epirubicin, paclitaxel, and cisplatin combination chemotherapy using EPO-based cytokine regimens: a randomized comparison of G-CSF and sequential GM-/G-CSF.
    Perillo A; Pierelli L; Scambia G; Serafini R; Paladini U; Salerno MG; Bonanno G; Fattorossi A; Leone G; Mancuso S; Menichella G
    Transfusion; 2001 May; 41(5):674-80. PubMed ID: 11346705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison.
    Pierelli L; Perillo A; Greggi S; Salerno G; Panici PB; Menichella G; Fattorossi A; Leone G; Mancuso S; Scambia G
    J Clin Oncol; 1999 Apr; 17(4):1288. PubMed ID: 10561191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of PBPC mobilization by cyclophosphamide, as compared with that by epirubicin/paclitaxel followed by G-CSF support: implications for optimal timing of PBPC harvest.
    Dettke M; Greinix HT; Kalhs P; Kührer I; Worel N; Höcker P
    Transfusion; 2001 May; 41(5):681-6. PubMed ID: 11346706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients.
    Filip S; Vanásek J; Bláha M; Mericka P; Vávrová J; Podzimek K
    Neoplasma; 1999; 46(3):166-72. PubMed ID: 10613592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
    Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
    J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.
    Somlo G; Sniecinski I; ter Veer A; Longmate J; Knutson G; Vuk-Pavlovic S; Bhatia R; Chow W; Leong L; Morgan R; Margolin K; Raschko J; Shibata S; Tetef M; Yen Y; Forman S; Jones D; Ashby M; Fyfe G; Hellmann S; Doroshow JH
    Blood; 1999 May; 93(9):2798-806. PubMed ID: 10216073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.
    Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K
    Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
    Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
    Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of growth factor administration and T-cell recovery after peripheral blood progenitor cell transplantation in the treatment of solid tumors: results from a randomized comparison of G-CSF and GM-CSF.
    Pierelli L; Perillo A; Ferrandina G; Salerno G; Rutella S; Fattorossi A; Battaglia A; Rughetti A; Nuti M; Cortesi E; Leone G; Mancuso S; Scambia G
    Transfusion; 2001 Dec; 41(12):1577-85. PubMed ID: 11778075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte-colony stimulating factor administered to patients with metastatic breast carcinoma.
    Bengala C; Pazzagli I; Tibaldi C; Favre C; Vanacore R; Greco F; Mazzoni A; Menconi MC; Macchia P; Conte PF
    Cancer; 1998 Mar; 82(5):867-73. PubMed ID: 9486575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of whole blood and peripheral blood progenitor cells (PBPC) and new strategies for rescue after intensive cyclic chemotherapy in high-risk breast cancer.
    Filip S; Bláha M; Odrázka K; Mericka P; Vávrová J
    J Hematother Stem Cell Res; 2000 Feb; 9(1):31-8. PubMed ID: 10738969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
    Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
    J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF.
    Ballestrero A; Ferrando F; Garuti A; Basta P; Gonella R; Stura P; Mela GS; Sessarego M; Gobbi M; Patrone F
    J Clin Oncol; 1999 Apr; 17(4):1296. PubMed ID: 10561192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
    Brugger W; Birken R; Bertz H; Hecht T; Pressler K; Frisch J; Schulz G; Mertelsmann R; Kanz L
    Br J Haematol; 1993 Jul; 84(3):402-7. PubMed ID: 7692928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage- and granulocyte-colony-stimulating factors.
    Lane TA; Ho AD; Bashey A; Peterson S; Young D; Law P
    Transfusion; 1999 Jan; 39(1):39-47. PubMed ID: 9920165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens.
    Cesana C; Regazzi E; Garau D; Caramatti C; Mangoni L; Rizzoli V
    Haematologica; 1999 Sep; 84(9):771-8. PubMed ID: 10477448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PBPC mobilization with paclitaxel, ifosfamide, and G-CSF with or without amifostine: results of a prospective randomized trial.
    Rick O; Schwella N; Beyer J; Dubiel M; Krusch A; Hildebrandt M; Schleicher J; Serke S; Siegert W
    Transfusion; 2001 Feb; 41(2):196-200. PubMed ID: 11239222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.